Systemic Lupus Erythematosus and Pregnancy

https://doi.org/10.1016/j.rdc.2016.12.009Get rights and content

Section snippets

Key points

  • Outcomes for pregnancy in the setting of systemic lupus erythematosus have considerably improved but the maternal and fetal risks still remain high.

  • Disease flares, preeclampsia, pregnancy loss, preterm births, intrauterine growth restriction, and neonatal lupus syndromes (especially heart block) remain the main complications.

  • Specific monitoring and treatment protocols need to be used for situations such as presence of specific antibodies (antiphospholipid antibodies and anti-Ro/La).

  • Safe and

Effects of pregnancy on systemic lupus erythematosus disease activity

Although opinions differ, most studies have shown that risk of SLE flare is higher during pregnancy. Variable flare rates of between 25% to 65% have been reported, likely attributable to different study designs, patient populations, and assessment tools being used.6, 7, 8 Multiple predictors for flares have been identified, including disease activity at the time of conception, lupus nephritis, and discontinuation of medications such as hydroxychloroquine (HCQ).9, 10 Most of these flares are

Effect of systemic lupus erythematosus on pregnancy outcomes

The interaction of SLE, an immune-mediated disease, and immunologic adaptations of pregnancy lead to unique challenges in this setting. Both mother and baby are at high risk of adverse pregnancy outcomes (APOs), including preeclampsia, preterm delivery, pregnancy loss, and intrauterine growth restriction (IUGR). The predictors of APO include active maternal disease, nephritis, proteinuria, hypertension, thrombocytopenia, and presence of antiphospholipid antibodies (aPLs), especially lupus

Management guidelines for pregnancy in systemic lupus erythematosus

Ideally, pregnancy should be timed during a period of disease quiescence because active disease at the time of conception is known to be one of the strongest predictors of APO. However, unplanned pregnancies are common, highlighting the often neglected need for contraceptive counseling in this group of women.42 Effective contraceptive choices include combined oral contraceptives in women with stable disease and negative aPL, progesterone-only contraceptives, and intrauterine devices, whereas

Summary

Pregnancy in women with SLE remains a high-risk condition despite considerable improvement in outcomes. Disease flares may occur during the pregnancy, and recognition and effective treatment are difficult but a realistic goal. High maternal and fetal mortality and morbidity are related to higher incidence of complications such as preeclampsia, pregnancy loss, preterm births, IUGR, and NLS, including CHB. Close monitoring, a tailored approach according to the specific risks involved, and

First page preview

First page preview
Click to open first page preview

References (70)

  • K. Levesque et al.

    Description of 214 cases of autoimmune congenital heart block: results of the French neonatal lupus syndrome

    Autoimmun Rev

    (2015)
  • C.A. Clark et al.

    Decrease in pregnancy loss rates in patients with systemic lupus erythematosus over a 40-year period

    J Rheumatol

    (2005)
  • M.E. Clowse et al.

    A national study of the complications of lupus in pregnancy

    Am J Obstet Gynecol

    (2008)
  • E.F. Chakravarty et al.

    Obstetric hospitalizations in the United States for women with systemic lupus erythematosus and rheumatoid arthritis

    Arthritis Rheum

    (2006)
  • M. Petri et al.

    Healthcare costs of pregnancy in systemic lupus erythematosus: retrospective observational analysis from a US health claims database

    J Med Econ

    (2015)
  • A. Lateef et al.

    Management of pregnancy in systemic lupus erythematosus

    Nat Rev Rheumatol

    (2012)
  • J. Cortes-Hernandez et al.

    Clinical predictors of fetal and maternal outcome in systemic lupus erythematosus: a prospective study of 103 pregnancies

    Rheumatology (Oxford)

    (2002)
  • D.D. Gladman et al.

    The effect of lupus nephritis on pregnancy outcome and fetal and maternal complications

    J Rheumatol

    (2010)
  • E. Imbasciati et al.

    Pregnancy in women with pre-existing lupus nephritis: predictors of fetal and maternal outcome

    Nephrol Dial Transplant

    (2009)
  • L.J. Jara et al.

    Risk factors of systemic lupus erythematosus flares during pregnancy

    Immunol Res

    (2014)
  • J.P. Buyon et al.

    Predictors of pregnancy outcomes in patients with lupus

    Ann Intern Med

    (2016)
  • M.E. Clowse et al.

    The clinical utility of measuring complement and anti-dsDNA antibodies during pregnancy in patients with systemic lupus erythematosus

    J Rheumatol

    (2011)
  • A. Lateef et al.

    Decrease in complement (C3) levels during systemic lupus erythematosus pregnancy is associated with higher rates of pre-eclampsia

    Arthritis Rheum

    (2010)
  • M. Ostensen et al.

    Anti-inflammatory and immunosuppressive drugs and reproduction

    Arthritis Res Ther

    (2006)
  • C. Gotestam Skorpen et al.

    The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation

    Ann Rheum Dis

    (2016)
  • R.J. Wapner et al.

    Long-term outcomes after repeat doses of antenatal corticosteroids

    N Engl J Med

    (2007)
  • M.E. Clowse et al.

    Hydroxychloroquine in lupus pregnancy

    Arthritis Rheum

    (2006)
  • R.A. Levy et al.

    Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study

    Lupus

    (2001)
  • P.M. Izmirly et al.

    Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus

    Circulation

    (2012)
  • P.M. Izmirly et al.

    Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine

    Ann Rheum Dis

    (2010)
  • W. Marder et al.

    In utero azathioprine exposure and increased utilization of special educational services in children born to mothers with systemic lupus erythematosus

    Arthritis Care Res (Hoboken)

    (2013)
  • M. Cassina et al.

    Pregnancy outcome in women exposed to leflunomide before or during pregnancy

    Arthritis Rheum

    (2012)
  • C.D. Chambers et al.

    Birth outcomes in women who have taken leflunomide during pregnancy

    Arthritis Rheum

    (2010)
  • R.J. Desai et al.

    Brief report: patterns and secular trends in use of immunomodulatory agents during pregnancy in women with rheumatic conditions

    Arthritis Rheumatol

    (2016)
  • M.E. Clowse et al.

    The impact of increased lupus activity on obstetric outcomes

    Arthritis Rheum

    (2005)
  • Cited by (0)

    Disclosures: The authors have no commercial or financial conflict of interest and no funding source for this work.

    View full text